drug

nerandomilast

1 story · latest Aug 27, 2026

Status: FDA approved Oct 2025 · NDA218764, NDA220449
Brand: Jascayd

Relationships

Developed by Boehringer Ingelheim

Timeline

Boehringer Ingelheim registers Phase 3 VERANDA-IIM trial of nerandomilast in myositis

Aug 27Trial updateBoehringer Ingelheim nerandomilast

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.